Short answer
Tonix Pharmaceuticals Holding Corp. (TNXP) filed its Q1 2026 10-Q quarterly report on May 11, 2026 for the quarter ended Mar 31, 2026. Quarterly revenue was $7M (up 183.2% year over year) with net income of −$40M.
Q1 2026 key financials · XBRL
- Revenue
- $7M
- +183.2% YoY
- Net income
- −$40M
- −138.8% YoY
- Operating margin
- -603.9%
- EPS (diluted)
- −$2.93
- −3.2% YoY
Source: XBRL data from the Tonix Pharmaceuticals Holding Corp. (TNXP) Q1 2026 10-Q on SEC EDGAR. USD.
Tonix Pharmaceuticals Holding Corp. Q1 2026 10-Q analysis
AI summary of MD&A and risk factor updates
Management Discussion & Analysis
- Product revenue $6.878M, up from $2.429M YoY
- TONMYA best performer at $3.731M; Tosymra weakest at $217K, down from $403K YoY
- Net loss $40.194M vs $16.829M; operating loss $41.537M vs $16.054M
- Cash $185.5M and operating cash use $42.318M vs $16.579M YoY
- $20.205M financing inflow from equity sales; liquidity expected into early Q2 2027, with additional funding required
Risk Factors
- No material changes to risk factors from December 31, 2025 Form 10-K
- Carried-forward risk factors potentially affecting business, financial condition, results, or cash flows
- Unknown or currently immaterial risks could later materially adversely affect financial position
Generated from the filing text; verify against the original. 10-K vs 10-Q vs 8-K
Other Tonix Pharmaceuticals Holding Corp. quarterly reports
Ask about this quarter
Compare quarters, check guidance or see what insiders and funds did around the report.